Free Trial
NASDAQ:ZVSA

ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis

ZyVersa Therapeutics logo
$0.0001 0.00 (0.00%)
As of 11/12/2026 02:04 PM Eastern

About ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

Advanced

Key Stats

Today's Range
$0.0001
▼
$0.0001
50-Day Range
$0.00
▼
$0.11
52-Week Range
$0.00
▼
$0.30
Volume
3,676 shs
Average Volume
30,169 shs
Market Capitalization
$793.60
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) is a clinical-stage biopharmaceutical company developing therapies for renal and inflammatory diseases. The company focuses on conditions in which abnormal lipid accumulation, inflammation and immune-system activity contribute to disease progression.

ZyVersa’s pipeline includes VAR 200, an investigational cholesterol efflux mediator being developed for kidney disorders such as focal segmental glomerulosclerosis and diabetic kidney disease. The company is also developing IC 100, an investigational inflammasome inhibitor designed to target NLRP3-driven inflammation and potentially address a range of inflammatory diseases.

The company is headquartered in Weston, Florida, and was founded in 2014. ZyVersa is led by co-founder Stephen C. Glover, who serves as chairman and chief executive officer. Its development programs are intended for patients with serious diseases for which additional treatment options are needed.

AI Generated. May Contain Errors.

Receive ZVSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZVSA Stock News Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
ZyVersa Therapeutics Delays 10-Q Filing
See More Headlines

ZVSA Stock Analysis - Frequently Asked Questions

ZyVersa Therapeutics' stock was trading at $0.1336 on January 1st, 2026. Since then, ZVSA shares have decreased by 99.9% and is now trading at $0.0001.

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.33.

ZyVersa Therapeutics's stock reverse split before market open on Friday, April 26th 2024.The 1-10 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ZyVersa Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Enphase Energy (ENPH), Ensysce Biosciences (ENSC), Cybin (HELP), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD).

Company Calendar

Today
11/13/2026
Next Earnings (Estimated)
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZVSA
CIK
1859007
Fax
N/A
Employees
2
Year Founded
2014

Profitability

EPS (Trailing Twelve Months)
($0.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.41 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-109.54%
Return on Assets
-43.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.18
Quick Ratio
0.18

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.40 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
7,936,000
Free Float
4,863,000
Market Cap
$793.60
Optionable
Not Optionable
Beta
1.01

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:ZVSA) was last updated on 11/12/2026 by MarketBeat.com Staff.
From Our Partners